Evaluating BioXcel Therapeutics as a potential investment requires assessing its artificial intelligence-driven drug re-innovation approach in neuroscience and immuno-oncology. While speculative investors are attracted to its innovative clinical pipeline and potential label expansions for agitation treatments, the high risk profile typical of clinical-stage biotech firms demands careful risk management and thorough due diligence.